Healthcare entity
Of the tracked stories, 2 of 3 also mention Moderna, the most common co-covered peer. Coverage clusters in market-trends, which accounts for 2 of those 3, with the remainder spread across 1 other category. Across a 41-day span, the pace is roughly 0.5 stories per week.
Last mentioned: 6d ago
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 33 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 2 of 3 also mention Moderna, the most common co-covered peer. Coverage clusters in market-trends, which accounts for 2 of those 3, with the remainder spread across 1 other category. Across a 41-day span, the pace is roughly 0.5 stories per week. At 6, the average consequence score sits above the same-window beat average of 5.5. Each story carries 2.7 original sources on average, compared with 2.4 for the broader beat in this window. We currently track 3 Healthcare stories that mention Novavax, published between August 4, 2026 and September 13, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 307 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Novavax. Shared-story counts are live from our verified record — not editorial picks.
Updated vaccines available
Updated COVID-19 and flu vaccines become available in the Bay Area.
Bay Area positivity hits 9%
State data show positive COVID-19 tests at moderate levels, slightly more than 9%.
Major SARS-CoV-2 variation emerges
A major viral variation emerges and is later named XFG or Stratus.
Trump administration relaxes COVID-19 vaccine recommendations
Federal recommendations are relaxed, creating widespread confusion in the Bay Area.
Updated COVID-19 and flu vaccines are now available across the Bay Area just as positive tests exceed 9%. Healthcare leaders need clear eligibility guidance and operational readiness for the 2026-27 respiratory season.
Moderna's mRNA cancer therapy readout sent its shares up as much as 177%, driving a 2.9% record gain in the S&P 500 healthcare sector amid easing Treasury yields. The rally lifted peers including Merck, BioNTech and Novavax, but macro rate worries persist.
Source: Sph Media (sg) · Reuters (my)
Wall Street Zen downgraded vaccine maker Novavax to sell, raising alarms in the healthcare sector. The stock traded at $7.41, far below its $13 consensus target, with a negative P/E of -12.78.
Novavax is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
